Restricted accessResearch articleFirst published online 2025
Efficacy and safety of casirivimab/imdevimab (REGEN-COV) in pregnant individuals with COVID-19: Literature review and insights from the COVID-19 International Drug Pregnancy Registry
Casirivimab/imdevimab (CAS/IMD) comprises two monoclonal antibodies that neutralize SARS-CoV-2. Pregnant individuals were excluded from initial trials, limiting safety data.
Methods
The COVID-19 International Drug Pregnancy Registry enrolled 53 pregnant women treated with CAS/IMD, with 34 live births.
Results
No safety concerns were identified.
Discussion and conclusions
The findings of the COVID-PR study support the safety of CAS/IMD during pregnancy, adding to the growing body of evidence on COVID-19 treatments for this population. The available literature shows that CAS/IMD is effective in preventing the progression to severe COVID-19 in pregnant individuals. The drugs are well-tolerated, and there is no compelling evidence of adverse maternal or neonatal outcomes. The results from the COVID-PR study are consistent with those of the broader literature.
DeeksED. Casirivimab/imdevimab: first approval. Drugs2021; 81: 2047–2055.
3.
BuonomoARFilippoIDEspositoN, et al.Outpatient use of monoclonal antibodies casirivimab and imdevimab in pregnancy for mild-to-moderate coronavirus disease 2019. Am J Perinatol2024; 41: 365–367.
4.
ChangMHCowmanKGuoY, et al.A real-world assessment of tolerability and treatment outcomes of COVID-19 monoclonal antibodies administered in pregnancy. Am J Obstet Gynecol2022; 226: 743–745.
5.
FolkmanRBlennowOTovattT, et al.Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy. Infection2023; 51: 261–263.
6.
HirshbergJSCookeEOakesMC, et al.Monoclonal antibody treatment of symptomatic COVID-19 in pregnancy: initial report. Am J Obstet Gynecol2021; 225: 688–689.
7.
LeveyNHForrestADSpielmanDW, et al.Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic. Am J Obstet Gynecol MFM2022; 4: 100673.
8.
MayerCVanHiseKCaskeyR, et al.Monoclonal antibodies casirivimab and imdevimab in pregnancy for coronavirus disease 2019 (COVID-19). Obstet Gynecol2021; 138: 937–939.
9.
MominA, et al.Threatened miscarriage in a COVID-19 patient. Cureus2022; 14: e31637.
10.
RiccardoBA, et al.Casirivimab and imdevimab for pregnant women hospitalized for severe coronavirus disease 2019. Am J Perinatol2022; 41: e612–e616.
11.
MagawaSNiiMMakiS, et al.Evaluation of the tolerability of monoclonal antibody therapy for pregnant patients with COVID-19. J Obstet Gynaecol Res2022; 48: 2325–2333.
12.
RichleyMRaoRRAfsharY, et al.Neutralizing monoclonal antibodies for coronavirus disease 2019 (COVID-19) in pregnancy: a case series. Obstet Gynecol2022; 139: 368–372.
13.
Casirivimab and imdevimab for COVID-19. Aust Prescr2022; 45: 58–59.
14.
MawaziSM, et al.REGEN-CoV and COVID-19, update on the drug profile and FDA status: a mini-review and bibliometric study. J Public Health Res2022; 10.
15.
Casirivimab and imdevimab (REGEN-COV) for post-exposure prophylaxis of COVID-19. Med Lett Drugs Ther2021; 63: 130–131.
16.
WilliamsFBMorganJAElmayanA, et al.Effectiveness of REGEN-COV combination monoclonal antibody infusion to reduce the risk of COVID-19 hospitalization in pregnancy: a retrospective cohort study. Am J Obstet Gynecol2023; 228: 102–103.
17.
WeinreichDM, et al.REGEN-COV antibody combination and outcomes in outpatients with COVID-19. N Engl J Med2021; 385: 81.
18.
Pham-HuyATopKAConstantinescuC, et al.The use and impact of monoclonal antibody biologics during pregnancy. Cmaj2021; 193: E1129–e1136.
19.
McCrearyEKLemonLMegliC, et al.Monoclonal antibodies for treatment of SARS-CoV-2 infection during pregnancy: a cohort study. Ann Intern Med2022; 175: 1707–1715.
20.
WyszynskiDF, et al.Use of sotrovimab in pregnancy: experiences from the COVID-19 international drug pregnancy registry. Drug Saf2024; 47: 843–851.
21.
WyszynskiDFPapageorghiouATRenzC, et al.The COVID-19 international drug pregnancy registry (COVID-PR): protocol considerations. Drug Saf2024; 47: 195–204.
22.
Hernandez-DiazSSmithLHDollingerC, et al.International registry of coronavirus exposure in pregnancy (IRCEP) - cohort description and methodological considerations. Am J Epidemiol2022; 191: 967–979.
23.
PageMJ, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J2021; 29: 1–9.
